Venus Pharma GmbH
A Pharmaceutical Hub in Germany

Venus Pharma GmbH, a European Pharmaceutical Company, is committed to delivering high-quality pharmaceutical products, building confidence with our clients, and providing exceptional services in the industry. With nearly 20 years of standing, we have established ourselves as are liable supplier of antibiotics and anticancer injectable drugs in Europe. Located in Germany, we serve as an extended arm of Venus Remedies Limited.

Contact

Your European Pharma Partner

With two decades of competence, Venus Pharma GmbH has been a trusted name in the pharmaceutical industry - Extensive PRODUCT PORTFOLIO Backed by Assured QUALITY & TIMELY DELIVERY

Quality

At Venus Pharma GmbH, quality is non-negotiable. We adhere to rigorous quality control measures to ensure that every product meets the highest safety and efficacy standards.

Extensive product basket

Witha diverse range of pharmaceutical products, we cater to a wide arrayof therapeutic areas and market segments. This comprehensive productportfolio enables us to meet the varied needs of our customerseffectively.

Timely deliveries

Recognizing the critical nature of timely deliveries in the pharmaceutical sector, we prioritize efficient supply chain management. Our streamlined processes ensure that orders are processed and dispatched promptly.

Company History

The way to represent the history same as previous website. Here are the
milestones by Years.

2024

VPG now holds 138+ Marketing Authorisations across 20 countries.

2022

Research studies presented at ESCMID & American Society for Microbiology (ASM) Microbe Conference. Invited as a speaker at the Indo-German Workshop on AMR in Berlin and Joint BSAC/GARDP Conference on Antimicrobial Chemotherapy.

2021

Research studies presented at ESCMID, World Microbe Forum, and BSAC’s Infection Conference. Supplied 4 million vials of Ceftriaxone to Iraq. Launched Meropenem in the UAE and Bahrain.

2020

Became the first company to introduce Meropenem 2000 mg. Received WHO Prequalification for Meropenem. Research studies presented at international conferences like the European Society of Clinical Microbiology and Infectious Diseases (ESCMID).

2019

Attained 50% market share in Italy.

2018

Established VPG as a hub for multiple business models, including: Tech Transfer, In-Licensing, Out-Licensing, Product Development, Site Variation, Packaging, Warehousing, and Batch Release.

2016

Successfully completed 10 years in the EU market, with intellectual capital as a primary business driver.

2015

Meropenem became VPG’s flagship product, securing 50% market share in Germany.

2013

Captured 33% of the UK market share for Gemcitabine through NHS tenders.

2012

Launched Anti-Cancer & Antibiotics portfolios in Germany & the UK.

2009

Expanded footprints in the prime Middle Eastern markets, focusing on Syria.

2007

Achieved first EU-GMP certification for the Indian manufacturing unit.

2006

Entered the German pharmaceutical space with the acquisition of a manufacturing facility at Werne, Germany, transforming it into Venus Pharma GmbH (VPG).